{"disease":{"id":"extranodal-nk-t-cell-lymphoma-nasal-type","name":"extranodal nk t cell lymphoma nasal type"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05907447","title":"A Retrospective Study on Extranodal Lymphoma or Lymphoma of Rare Pathological Types","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT05978141","title":"A Registry for People With T-cell Lymphoma","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT03079544","title":"Social Media-based Active Self-report on Incidence and Outcomes of Adverse Events in NK/TCL Patients","phase":"","overall_status":"COMPLETED","enrollment_count":665,"lead_sponsor_name":"Rong Tao","has_results":false},{"nct_id":"NCT02085655","title":"PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":264,"lead_sponsor_name":"Huiqiang Huang","has_results":false},{"nct_id":"NCT02631239","title":"MESA Versus ESA in the Treatment of Early Stage NK/T-cell Lymphoma","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":256,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT00536601","title":"High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors","phase":"NA","overall_status":"COMPLETED","enrollment_count":174,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT01529827","title":"Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":94,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT03493451","title":"Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":77,"lead_sponsor_name":"BeiGene","has_results":true},{"nct_id":"NCT00856388","title":"Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders","phase":"NA","overall_status":"COMPLETED","enrollment_count":62,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT05254899","title":"Anti-PD-1 Antibody and P-GEMOX Chemotherapy Combined With Radiotherapy in High-risk Early-Stage ENKTL","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":54,"lead_sponsor_name":"Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT04509466","title":"Clinical Study of Liposomal Mitoxantrone Hydrochloride Injection Combined With Pegaspargase in the Treatment of NKTCL","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":41,"lead_sponsor_name":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","has_results":false},{"nct_id":"NCT04676789","title":"Anti-PD-1 Antibody and Pegaspargase Combined With Radiotherapy in Early-Stage ENKTL","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT05149170","title":"Radiotherapy and Anti-PD-1 in Low-risk ES-ENKTCL","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT04405375","title":"GPED Regimen for Relapsed/Refractory or Advanced ENKTCL","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":29,"lead_sponsor_name":"Beijing Tongren Hospital","has_results":false},{"nct_id":"NCT02652715","title":"Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma","phase":"NA","overall_status":"COMPLETED","enrollment_count":29,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT04414163","title":"A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":23,"lead_sponsor_name":"ImmuneOncia Therapeutics Inc.","has_results":false},{"nct_id":"NCT04338282","title":"Maintenance Therapy With Anti-PD-1 Antibody for Patients With NK/T-cell Lymphoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Beijing Tongren Hospital","has_results":false},{"nct_id":"NCT04602065","title":"Evaluation of Safety and Efficacy of IBI318 Monotherapy for Relapsed/Refractory Extranodal NK/T Cell Lymphoma (Nasal Type) Trial","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":9,"lead_sponsor_name":"Innovent Biologics (Suzhou) Co. Ltd.","has_results":false},{"nct_id":"NCT04639843","title":"Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma","phase":"PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false}],"total":19},"guidelines":[],"source":"Drug Landscape verified database"}